G

Genovis AB
STO:GENO

Watchlist Manager
Genovis AB
STO:GENO
Watchlist
Price: 24.55 SEK -1.6% Market Closed
Market Cap: 1.6B SEK
Have any thoughts about
Genovis AB?
Write Note

Genovis AB
Investor Relations

Genovis AB engages in the research and development of enzyme products. The company is headquartered in Lund, Skane. The company went IPO on 2005-11-11. The firm offers products within two product portfolios, namely protein portfolio and nano portfolio. The protein portfolio develops products within the areas of cancer, inflammatory and autoimmune diseases. The portfolio comprises FabRICATOR, a genetically modified enzyme the cleaves antibodies in two parts, and IgGZERO, a protein that specifically cleaves the sugar molecules that occur naturally on antibodies. The products within the nano portfolio are primarily directed at the preclinical market. The firm markets and sells its products through dealers and distributors in the European, North American and Asian continents. As of December 31, 2011, it operated a wholly owned subsidiary, Eijdo Research AB.

Show more

Earnings Calls

No Earnings Calls Available

Management

Mr. Fredrik Olsson
President & CEO
No Bio Available
Mr. Magnus Langberg
Group Chief Financial Officer
No Bio Available
Ms. Rikke Rytter
Vice President of Sales & Marketing
No Bio Available
Ms. Maria Edholm
Controller
No Bio Available
Mr. John M. Lindsay B.A., BA
President of Genovis Inc.
No Bio Available

Contacts

Address
SKANE
Lund
Medicon Village, Scheelevagen 2
Contacts
+4646101230.0
www.genovis.com